Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone - Wikidata - awgldk - TriplyDB

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

http://www.wikidata.org/entity/Q35068005

about

Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Therapy assessment in prostate cancer using choline and PSMA PET/CT.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.The use of PET/CT in prostate cancer.Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.Positron emission tomography in prostate cancer: An update on state of the art PET/CT analysis of 21 patients with breast cancer: physiological distribution of F-choline and diagnostic pitfalls

P2860

Q26765882-426CCBD4-93CE-4040-83C8-3547F3A8EFBC Q28071705-A91B59DC-0AEF-4030-A0C6-D98C5683F335 Q33689314-B6442FC6-3AB6-4FEA-90BE-1E58832DEBD1 Q35603660-737E2035-3215-45D0-8D98-5381CFBC4E87 Q35925260-76AE7E77-30CC-4BAB-A671-D1CF20723C46 Q36025254-23271DB2-3FF9-426E-8351-CBCCFDE9ED07 Q37496697-07A1492D-F3F8-404A-AEC5-A89EB10938AB Q38766102-D150FEDF-D699-41A0-B17D-FC1583358CA8 Q38827364-45157E24-790B-4695-8CC3-BBB42A9635FE Q38920663-129D9DD1-0F10-42A8-8BB0-A8B1918E8AC5 Q39242140-E71F4E57-3EDE-40EF-8399-D12FB194A74D Q39328036-41A85C66-3C72-4DBB-BB60-2B49B8A89935 Q39699773-AC8AD9FE-E2BE-4BBC-A310-9F2F68EBEF0A Q41161118-8BD50B53-D68B-4A05-97A7-3E1DA8F83E0F Q41867950-6DF531E1-6EAD-4510-B9CC-3DBD0C402B7B Q42174990-F5FFF5CE-EFD3-47F3-BAD8-82BDFA00783F Q44453209-3D33E0B1-C4BC-4BDB-9547-33FB854F464A Q47399411-BE8CDD9B-8A86-4DB2-9859-62723D1D8BB3 Q47645575-67E9533B-C801-4C45-9EA9-B7916751F2A2 Q48139886-C009A5DF-8114-402C-8244-16ACFA240AA6 Q49919217-50C5B167-B762-47DB-B915-94DEBC62D587 Q52982270-81D46D50-F346-49DE-920B-49D8A0B1AE39 Q52990015-0FFF9C98-4BF4-4EDE-A735-36A269A49426 Q53772593-016EA0AE-9EC0-46BF-912A-F7C9C78F79DA Q55020746-6931BE55-4F44-4B8C-A569-003153F35797 Q57110351-71D43EE5-A5D4-45B8-AD7E-3C671EC890D1 Q57642100-ECD10BAE-80AF-457C-999E-A7B3E9B76197

P2860

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

http://www.wikidata.org/entity/Q35068005

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Early outcome prediction on 18 ...... ients treated with abiraterone

@ast

Early outcome prediction on 18 ...... ients treated with abiraterone

@en

type

label

Early outcome prediction on 18 ...... ients treated with abiraterone

@ast

Early outcome prediction on 18 ...... ients treated with abiraterone

@en

prefLabel

Early outcome prediction on 18 ...... ients treated with abiraterone

@ast

Early outcome prediction on 18 ...... ients treated with abiraterone

@en

P1433

Q35068005-B730348D-7AB2-4E1C-95FA-A3C8DEEB24EE

P1476

Q35068005-9A448F3F-F81E-4826-B100-373147329286

P2093

Q35068005-2FA4087A-09E0-47FB-9E33-94532E7A1321

Q35068005-3751387A-8BE9-4466-977F-A08131283D63

Q35068005-53FF5735-225C-441D-9BD3-778EF13A0B7C

Q35068005-600B3258-57E0-4E65-A2CE-35EAF7522184

Q35068005-6296C88D-151F-462E-9F34-CA62512666FD

Q35068005-67240D5E-53B0-40B4-8C7B-7C8AA3F56149

Q35068005-681D3914-5796-40D6-B139-ED71441A7694

Q35068005-8EBCE818-D9FC-4745-90E7-BBE2967ED3EF

Q35068005-BFDE9134-56D9-4DED-A6F4-42B400787868

Q35068005-D7AC8FE6-1857-4AF8-941C-B17200C9843F

P2860

Q35068005-0807B347-CF23-4DCB-A488-79F129677764

Q35068005-100AA9A7-DE42-4BD0-8F5A-5BEBECBC32CF

Q35068005-11883C52-078E-4081-B4FB-9C2B3929657D

Q35068005-19D0FF2C-68A8-4774-99C9-401461A114B7

Q35068005-1F61E551-C62F-4531-90EE-7062B94E02B9

Q35068005-20BE0611-3EE4-4E0F-B70E-ADF7D8C66C92

Q35068005-2600E5D0-41F2-4965-A8F8-FEC1FA6D5DDA

Q35068005-39C612B5-9C73-467D-B593-554B11C8E9D3

Q35068005-3B355933-AF5C-40DB-A070-C0915DC1194F

Q35068005-465C7029-0444-43FB-9C95-B31EABCF262C

P304

Q35068005-DD6144D6-9EDF-499E-A29E-1CEAE7595063

P31

Q35068005-A8744E58-A276-4ECC-B74B-EFCDB6651C73

P356

Q35068005-4D787717-69BC-4CC7-9D28-C9914B030E87

P407

Q35068005-5570F66D-CBF0-4559-81A8-B18979D27383

P433

Q35068005-01BC79E6-6085-43CD-8CD5-67C4F46AF3E8

P478

Q35068005-853B3D91-574D-4EC3-A536-404B7BAF59EC

P577

Q35068005-0C75654D-39C5-45D0-8B6F-8AD56363A20F

P5875

Q35068005-B1A00812-2815-4357-B5A3-AFA68FDFEF18

P698

Q35068005-EDFB63FB-71D8-4691-BA5C-3250D4FA3832

P932

Q35068005-73575425-46B9-4C7E-97C1-B3887371C469

P356

ONCOTARGET.2558

P1433

P1476

Early outcome prediction on 18 ...... ients treated with abiraterone

@en

P2093

Cecilia Menna

http://www.w3.org/2001/XMLSchema#string

Dino Amadori

http://www.w3.org/2001/XMLSchema#string

Elisa Carretta

http://www.w3.org/2001/XMLSchema#string

Emanuela Bianchi

http://www.w3.org/2001/XMLSchema#string

Federica Matteucci

http://www.w3.org/2001/XMLSchema#string

Francesca Fabbri

http://www.w3.org/2001/XMLSchema#string

Giovanni Paganelli

http://www.w3.org/2001/XMLSchema#string

Paola Caroli

http://www.w3.org/2001/XMLSchema#string

Salvatore L Burgio

http://www.w3.org/2001/XMLSchema#string

Ugo De Giorgi

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Abiraterone and increased survival in metastatic prostate cancer

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

The contribution of PET/CT to improved patient management.

Positron-emission tomography and assessment of cancer therapy.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

P304

12448-12458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2558

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269715982

http://www.w3.org/2001/XMLSchema#string

P698

25504434

http://www.w3.org/2001/XMLSchema#string

P932

4322993

http://www.w3.org/2001/XMLSchema#string